Close Menu

Bruker Reports Strong Q3, Considerable TOF/TOF Sales to Academic Institutions

Having spilled some of its goodies already in an October presentation at an investors’ meeting (see ProteoMonitor, 10-21-02), Bruker Daltonics formally reported last week that its revenues were up 22 percent for the third quarter. These revenues totaled $29.7 million, compared to $23.8 million in the third quarter of 2001. The company’s net income totaled $1.7 million, up from $925,000 in the previous year’s third quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.